Denmark's Lundbeck predicts growth in 2023 revenue and earnings
OSLO, Feb 7 (Reuters) - Danish drug maker Lundbeck
HLUNDb.CO predicted on Tuesday its revenue would grow in 2023
to between 19.4 billion and 20 billion Danish crowns ($2.79
billion-$2.88 billion) from 18.2 billion crowns last year.
Earnings before interest, tax, depreciation and amortisation
(EBITDA) is meanwhile expected to rise to between 4.8 billion
and 5.2 billion crowns from 4.66 billion in 2022, the company
said in a statement.
($1 = 6.9506 Danish crowns)
(Reporting by Terje Solsvik, editing by Essi Lehto)
((terje.solsvik@thomsonreuters.com; +47 918 666 70))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options